A Phase 3 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Takeda. Completed at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-03.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.
Among the 10 studies testing vonoprazan in Esophagitis, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 5th registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 18+
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2015.
This study's enrollment of 481 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 357 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
11 studies in Esophagitis by Takeda: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Esophagitis by Takeda, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 7th registered.
Takeda’s Esophagitis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 11 in Esophagitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
The drug being tested in this study is called vonoprazan. Vonoprazan is being tested to treat people who have erosive esophagitis. This study will look at mucosal healing of people who take vonoprazan versus lansoprazole.
This study will enroll approximately 480 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one tablet and one capsule at the same time each day throughout the study. All participants will be asked to record daytime and nighttime (during sleep) subjective symptoms in a diary on a daily basis.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 11 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 7-14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has been confirmed in an endoscopy to have erosive esophagitis, ie, the Los Angeles (LA) classification grades A to D within 7 days of the start of the Day 1 (Visit 2).
Note: The recruitment goal is to ensure that those with LA classification grade C/D will account for more than 30% of all participants enrolled (144/480), with no further recruitment of those with grade A/B considered when they account for more than 70% (336/480) of all participants.
Exclusion Criteria:
Has a history of or allergies to TAK-438 (including its *) or to proton pump inhibitors (PPIs).
*D-mannitol, crystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 6000, titanium oxide, yellow iron sesquioxide and iron sesquioxide.
Laboratory tests performed at the start of the Early Observation Phase (visit 1) revealed any of the following abnormalities in the participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
Drug: Vonoprazan · Drug: Lansoprazole Placebo
Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
Drug: Lansoprazole · Drug: Vonoprazan Placebo
Vonoprazan tablets
Also known as: TAK-438
Lansoprazole capsules
Also known as: Prevacid
Vonoprazan placebo-matching tablets
Lansoprazole placebo-matching capsules
Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase
Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.
Time frame: 8 weeks
Percentage of Participants With Endoscopic Healing of Erosive Esophagitis After 2 Weeks and 4 Weeks of Treatment
Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.
Time frame: Week 2 and Week 4
Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.
Time frame: On or after the start of study drug (Day 1) to 14 days after the last dose of study medication (up to 10 weeks)
Number of Participants With Markedly Abnormal Clinical Laboratory Findings
Clinical Laboratory Safety tests included Chemistry, Hematology and Urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings
Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
Number of Participants With Markedly Abnormal Vital Sign Measurements
Number of participants with any markedly abnormal vital signs measurements is reported. Vital signs included body temperature (oral, tympanic, or infra-axillary measurement), sitting blood pressure (5 minutes), and pulse. °C = degrees Celsius, mmHg = millimeters of mercury, bpm = beats per minute.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
Change From Baseline in Serum Gastrin
The change between the serum gastrin values collected at Weeks 2, 4, and 8 relative to baseline.
Time frame: Baseline and Weeks 2, 4, and 8
Change From Baseline in Serum Pepsinogen I
The change between the serum pepsinogen I values collected at Weeks 2, 4, and 8 relative to baseline.
Time frame: Baseline and Weeks 2, 4, and 8
Change From Baseline in Serum Pepsinogen II
The change between the serum pepsinogen II values collected at Weeks 2, 4, and 8 relative to baseline.
Time frame: Baseline and Weeks 2, 4, and 8
Participants took part in the study at 56 investigative sites in China, Korea, Taiwan, and Malaysia from 24 March 2015 to 27 July 2017.
| Milestone | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Started | 244 | 237 |
| Safety set: randomized but not treated | 0 | 2 |
| Completed | 232 | 224 |
| Not completed | 12 | 13 |
| Withdrew: Reason not specified | 0 | 1 |
| Withdrew: Major protocol deviation | 3 | 3 |
| Withdrew: Pretreatment event/adverse event | 3 | 2 |
| Withdrew: Voluntary withdrawal | 6 | 5 |
| Withdrew: Randomized but not treated | 0 | 2 |
Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.
| percentage of participants | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase | 92.4 (88.310 to 95.456) | 91.3 (86.890 to 94.607) |
Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.
| percentage of participants | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| 2 Weeks | 75.0 (68.970 to 80.391) | 67.8 (61.341 to 73.869) |
| 4 Weeks | 85.3 (80.146 to 89.538) | 83.5 (78.035 to 88.035) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.
| Participants | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE) | 93 | 86 |
Clinical Laboratory Safety tests included Chemistry, Hematology and Urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.
| Participants | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Hemoglobin (<0.8 x LLN g/L) | 0 | 1 |
| Neutrophils (<0.5 x LLN %) | 0 | 2 |
| Eosinophils (>2 x ULN %) | 1 | 0 |
| Lymphocytes (>1.5 x ULN %) | 0 | 2 |
| ALT (>3 x ULN U/L) | 0 | 2 |
| AST (>3 x ULN U/L) | 0 | 1 |
| GGT (>3 x ULN U/L) | 4 | 3 |
| CPK (>5 x ULN U/L) | 1 | 2 |
| Total Protein (>1.2 x ULN g/L) | 0 | 1 |
| BUN (>10.7 mmol/L) | 1 | 1 |
| Total Cholesterol (>7.72 mmol/L) | 3 | 2 |
| Triglycerides (>2.5 x ULN mmol/L) | 6 | 3 |
| Vitamin B12 (<92 pmol/L) | 0 | 1 |
Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.
| Participants | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Heart Rate (<50 bpm) | 6 | 7 |
| QT Interval (≥460 msec) | 7 | 10 |
| QTcF Interval (≥500, or ≥450 with CHG ≥30 msec) | 3 | 5 |
Number of participants with any markedly abnormal vital signs measurements is reported. Vital signs included body temperature (oral, tympanic, or infra-axillary measurement), sitting blood pressure (5 minutes), and pulse. °C = degrees Celsius, mmHg = millimeters of mercury, bpm = beats per minute.
| Participants | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Body Temperature (<35.6 °C) | 10 | 3 |
| Body Temperature (>37.7 °C) | 2 | 0 |
| Systolic Blood Pressure (<85 mmHg) | 1 | 1 |
| Diastolic Blood Pressure (>110 mmHg) | 1 | 0 |
| Pulse (<50 bpm) | 2 | 2 |
The change between the serum gastrin values collected at Weeks 2, 4, and 8 relative to baseline.
| pmol/L | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Baseline | 2.77 ± 4.084 | 3.65 ± 8.622 |
| Change at Week 2 | 31.45 ± 28.995 | 8.33 ± 10.190 |
| Change at Week 4 | 29.68 ± 29.189 | 6.81 ± 9.969 |
| Change at Week 8 | 36.53 ± 37.108 | 4.71 ± 7.727 |
The change between the serum pepsinogen I values collected at Weeks 2, 4, and 8 relative to baseline.
| micrograms per liter (ug/L) | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Baseline | 97.6 ± 53.54 | 99.8 ± 61.99 |
| Change at Week 2 | 456.5 ± 308.22 | 129.3 ± 138.24 |
| Change at Week 4 | 421.8 ± 324.06 | 118.3 ± 113.24 |
| Change at Week 8 | 326.8 ± 233.80 | 117.8 ± 98.03 |
The change between the serum pepsinogen II values collected at Weeks 2, 4, and 8 relative to baseline.
| ug/L | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Baseline | 7.5 ± 5.50 | 7.8 ± 5.77 |
| Change at Week 2 | 44.9 ± 31.31 | 8.8 ± 9.63 |
| Change at Week 4 | 40.7 ± 26.10 | 7.2 ± 5.99 |
| Change at Week 8 | 31.0 ± 20.03 | 8.0 ± 8.46 |
Collected over Up to 10 weeks (8 weeks of treatment and 2 weeks of post-treatment follow-up period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vonoprazan 20 mg | 0/244 (0%) | 3/244 (1.2%) | 13/244 (5.3%) |
| Lansoprazole 30 mg | 0/235 (0%) | 3/235 (1.3%) | 4/235 (1.7%) |
| Event | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| GlaucomaEye disorders | 0/244 | 1/235 |
| Large intestine polypGastrointestinal disorders | 0/244 | 1/235 |
| GastroenteritisInfections and infestations | 0/244 | 1/235 |
| Bile duct stoneHepatobiliary disorders | 1/244 | 0/235 |
| Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/244 | 0/235 |
| Cerebral infarctionNervous system disorders | 1/244 | 0/235 |
| Event | Vonoprazan 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Blood gastrin increasedInvestigations | 13/244 | 4/235 |
Randomized set included all randomized participants.
| Age, Continuous(years) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 54.1 ± 13.16 | 53.8 ± 12.53 | 53.9 ± 12.84 |
| Sex: Female, Male(Participants) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Female | 68 | 58 | 126 |
| Male | 176 | 179 | 355 |
| Race/Ethnicity, Customized(Participants) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Asian | 244 | 237 | 481 |
| Region of Enrollment(Participants) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Asia — China | 143 | 133 | 276 |
| Asia — Malaysia | 21 | 24 | 45 |
| Asia — South Korea | 52 | 55 | 107 |
| Asia — Taiwan | 28 | 25 | 53 |
| Height(centimeters (cm)) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 166.1 ± 8.24 | 166.3 ± 8.80 | 166.2 ± 8.52 |
| Weight(kilograms (kg)) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 68.48 ± 12.311 | 70.26 ± 12.133 | 69.35 ± 12.243 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 24.70 ± 3.389 | 25.31 ± 3.430 | 25.00 ± 3.419 |
| Smoking Classification(Participants) | Vonoprazan 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Never Smoked | 157 | 137 | 294 |
| Current Smoker | 48 | 64 | 112 |
| Ex-Smoker | 39 | 36 | 75 |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Jul 2017, 28 months.
Results were first posted in Jun 2019, 1 year 10 months after primary completion.
Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 28 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan